US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
ドイツ
TG
Corvus Pharmaceuticals Inc (C17) 銘柄情報

Corvus Pharmaceuticals Inc (C17)

14.06

0.00

( 0.00% )

更新日時： 18:14:11

Corvus Pharmaceuticals Inc (C17) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

14.06

( - )

買値

14.01

売値

14.36

出来高

0.00

0.00 日の範囲 0.00

3.505 52 週間の範囲 22.90

前日終値

14.06

始値

-

時刻

最終取引時間

-

平均取引量 (3 か月)

1,935

財務取引量

-

VWAP

-

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.21	1.51624548736	13.85	14.06	13.46	91	14.02770073	DE
4	3.91	38.5221674877	10.15	14.06	10.15	664	11.29773801	DE
12	1.49	11.8536197295	12.57	16.45	9.518	1935	12.30005148	DE
26	8.18	139.115646259	5.88	22.9	5.72	2505	15.26593759	DE
52	10.44	288.397790055	3.62	22.9	3.505	2690	10.47473883	DE
156	11.96	569.523809524	2.1	22.9	1.01	1916	8.00067854	DE
260	11.96	569.523809524	2.1	22.9	1.01	1916	8.00067854	DE

C17 - Frequently Asked Questions (FAQ)

What is the current Corvus Pharmaceuticals Inc share price?

The current share price of Corvus Pharmaceuticals Inc is 14.06 €

What is the 1 year trading range for Corvus Pharmaceuticals Inc share price?

Corvus Pharmaceuticals Inc has traded in the range of 3.505 € to 22.90 € during the past year

new-stocks

new-stocks 5分前

https://getmysocial.com/tina9

Sideem

I asked ChatGPT the following:

"Why is BBUL shares selling for almost twice the price of regular BB shares?"

This catches a lot of people by surprise, but the price of BBUL is not supposed to equal—or even be close to—the price of BB stock.

The ETF sponso

new-stocks

new-stocks 14分前

https://linktw.in/UQjike

new-stocks

new-stocks 14分前

https://linktw.in/UQjike

new-stocks

new-stocks 15分前

https://linktw.in/UQjike

JRyan

Is ZNOG A Good Investment? An Honest Assessment

https://i.postimg.cc/dV8XpJmX/New-To-ZNOG-Fig1-License-Map.jpg
(Figure 1. The Megiddo-Jezreel License — the single asset on which this entire company depends. ~75,000 acres. License 434 base term expires September 13, 2026.)

north40000

north40000 21分前

Substitute 9% for $19 Billion. ATTR-CM is the heart condition treated with other stabilizers that failed in Phase 3 trial. Has Vascepa been in clinical trials for that condition?

tkg

A good 2:13m video in link...

https://x.com/SanCompounding/status/2074871489476878370

new-stocks

new-stocks 33分前

https://linktw.in/UQjike

new-stocks

new-stocks 33分前

https://linktw.in/UQjike

new-stocks

new-stocks 34分前

https://linktw.in/UQjike

new-stocks

new-stocks 34分前

https://linktw.in/UQjike

new-stocks

new-stocks 34分前

https://linktw.in/UQjike

new-stocks

new-stocks 34分前

https://linktw.in/UQjike

new-stocks

new-stocks 35分前

https://linktw.in/UQjike

new-stocks

new-stocks 35分前

https://linktw.in/UQjike

new-stocks

new-stocks 36分前

https://linktw.in/UQjike

new-stocks

new-stocks 37分前

https://linktw.in/UQjike

new-stocks

new-stocks 38分前

https://linktw.in/UQjike

new-stocks

new-stocks 39分前

https://linktw.in/UQjike

north40000

north40000 48分前

AZN major clinical trial failure/setback with gene-silencing Wainua drug partnered with IONS. AZN stock drops ~ $19 Billion. Bloomberg news is source.

Corvus Pharmaceuticals

Investec Bnk 23

DJ Commodity Index 2X In...

Nexien BioPharma (EM)

XS2783658086 20280428 67...

Xtrackers EUR High Yield...

Ameriwest Lithium

CAC Climate Transition

State Street SPDR Portfo...

Australian Strategic Mat...

Euronext Saint Gobain PR

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。